<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144635</url>
  </required_header>
  <id_info>
    <org_study_id>KULDS-001</org_study_id>
    <nct_id>NCT03144635</nct_id>
  </id_info>
  <brief_title>A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir</brief_title>
  <official_title>A Prospective Multicenter Observational Study for Characterization of Renal Function G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may
      safely be used for the elderly patients with renal dysfunction. Grazoprevir and elbasvir are
      metabolized in the liver and do not require dose-adjustment for patients with renal
      dysfunction. However, no data related to efficacy and safety of the grazoprevir plus elbasvir
      treatment for Japanese elderly patients with renal dysfunction (eGFR&lt;60 mL/min/1.73m2) have
      been reported. Therefore, physicians are at a loss whether or not to treat the patients with
      renal dysfunction due to no evidence.

      The aim of this study is to investigate the improvement of serum endostatin level of Japanese
      patients with CKD stage 3 after grazoprevir (NS3/4A protease inhibitor) plus elbasvir (NS5A
      replication complex inhibitor) treatment by a prospective, multicenter cohort study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Serum Endostatin Level (ng/mL) From Baseline to 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>We evaluated the serum endostatin at baseline and 3 months after the treatment initiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of eGFR Level (mL/Min/1.73m^2) From Baseline to 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>We evaluated eGFR level at baseline and 3 months after the treatment initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virological Response-12 (SVR12)</measure>
    <time_frame>3 months</time_frame>
    <description>SVR12 was defined as undetectable HCV RNA at week 12 after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum Alanine Aminotransferase (ALT) Level (U/L) From Baseline to 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>We evaluated the serum ALT levels at baseline and 3 months after the treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum Alpha-fetoprotein Level (ng/mL) From Baseline to 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>We evaluated the serum alpha-fetoprotein levels at baseline and 3 months after the treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With NS3/4A or NS5A Muttations Who Achieved SVR12</measure>
    <time_frame>3 months</time_frame>
    <description>We identified the NS3/4A or NS5A muttations by direct sequencing at baseline. Among participants who had mutations, we calcualted the rate of SVR12.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hepatitis C Viral</condition>
  <condition>Chronic Kidney Disease stage3</condition>
  <arm_group>
    <arm_group_label>Grazoprevir plus Elbasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir plus Elbasvir</intervention_name>
    <description>An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
    <arm_group_label>Grazoprevir plus Elbasvir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged 20 years or older.

          2. Patients positive for HCV RNA for over 6 months and infected with genotype 1b chronic
             hepatitis C, including compensated cirrhosis.

          3. Patients without co-infection of hepatitis B virus.

          4. Patients without co-infection of human immunodeficiency virus

          5. Patients with moderate chronic kidney disease (CKD stage 3) (eGFR: 30-59
             mL/min/1.73m2). A diagnosis of CKD is only confirmed if repeated eGFR tests for at
             least 90 days.

        Exclusion Criteria:

          1. Patients with decompensated cirrhosis (Child Pugh B and C)

          2. Patients with albumin &lt;3.0 g/dL and platelets &lt;75,000 /μL

          3. Patients with autoimmune hepatitis

          4. Constant heavy alcohol drinkers (converted to ethanol ≥60 g/day)

          5. Patients who have a history of hypersensitivity to grazoprevir and elbasvir

          6. Patients who are pregnant females, or females who may become pregnant, or females who
             are breastfeeding

          7. Patients with heart disease that is hard to control (e.g., very recent cardiac
             infarction, severe heart failure, unstable arrhythmia)

          8. Patients who are under medication with drugs listed as contraindication in a package
             insert of grazoprevir plus elbasvir treatment

          9. Patients judged (by the physician in charge of research) to be inappropriate as
             subjects for the study for any other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norihiro Furusyo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020. Epub 2013 Mar 28.</citation>
    <PMID>23542346</PMID>
  </reference>
  <reference>
    <citation>Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study(KULDS) Group. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatol Res. 2017 Mar;47(3):E120-E131. doi: 10.1111/hepr.12738. Epub 2016 Jun 10.</citation>
    <PMID>27142311</PMID>
  </reference>
  <reference>
    <citation>Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol. 2015 Dec;30(12):1759-67. doi: 10.1111/jgh.13016.</citation>
    <PMID>26095167</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <results_first_submitted>September 21, 2018</results_first_submitted>
  <results_first_submitted_qc>February 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyushu University</investigator_affiliation>
    <investigator_full_name>Norihiro Furusyo</investigator_full_name>
    <investigator_title>Associate Professor, Department of General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Direct Acting Antivirals</keyword>
  <keyword>Grazoprevir</keyword>
  <keyword>Elbasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK-5172</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03144635/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Grazoprevir Plus Elbasvir</title>
          <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Grazoprevir Plus Elbasvir</title>
          <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="69" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" lower_limit="20.7" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="3.6" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate aminotransferase</title>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="31" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase</title>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="24" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gamma-glutamyl transpeptidase</title>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="19" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>alpha-fetoprotein</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" lower_limit="3.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cirrhosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA level</title>
          <units>logIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" lower_limit="5.9" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Naive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV NS5A RAS</title>
          <description>We identified the following as amino-acid resistance-associated substitutions (RAS) to non-structual 5A (NS5A) inhibitor by direct sequencing: NS5A gene amino acid positions 30, 31, and 93 for patients infected with HCV were examined at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Serum Endostatin Level (ng/mL) From Baseline to 3 Months</title>
        <description>We evaluated the serum endostatin at baseline and 3 months after the treatment initiation.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir Plus Elbasvir</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum Endostatin Level (ng/mL) From Baseline to 3 Months</title>
          <description>We evaluated the serum endostatin at baseline and 3 months after the treatment initiation.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of eGFR Level (mL/Min/1.73m^2) From Baseline to 3 Months</title>
        <description>We evaluated eGFR level at baseline and 3 months after the treatment initiation.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir Plus Elbasvir</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of eGFR Level (mL/Min/1.73m^2) From Baseline to 3 Months</title>
          <description>We evaluated eGFR level at baseline and 3 months after the treatment initiation.</description>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virological Response-12 (SVR12)</title>
        <description>SVR12 was defined as undetectable HCV RNA at week 12 after the end of treatment.</description>
        <time_frame>3 months</time_frame>
        <population>Three patients discontinued treatment due to adverse effects.</population>
        <group_list>
          <group group_id="O1">
            <title>Intention-to-treat Populations</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Per-protocol Populations</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virological Response-12 (SVR12)</title>
          <description>SVR12 was defined as undetectable HCV RNA at week 12 after the end of treatment.</description>
          <population>Three patients discontinued treatment due to adverse effects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Serum Alanine Aminotransferase (ALT) Level (U/L) From Baseline to 3 Months</title>
        <description>We evaluated the serum ALT levels at baseline and 3 months after the treatment initiation.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir Plus Elbasvir</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum Alanine Aminotransferase (ALT) Level (U/L) From Baseline to 3 Months</title>
          <description>We evaluated the serum ALT levels at baseline and 3 months after the treatment initiation.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Serum Alpha-fetoprotein Level (ng/mL) From Baseline to 3 Months</title>
        <description>We evaluated the serum alpha-fetoprotein levels at baseline and 3 months after the treatment initiation.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir Plus Elbasvir</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum Alpha-fetoprotein Level (ng/mL) From Baseline to 3 Months</title>
          <description>We evaluated the serum alpha-fetoprotein levels at baseline and 3 months after the treatment initiation.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With NS3/4A or NS5A Muttations Who Achieved SVR12</title>
        <description>We identified the NS3/4A or NS5A muttations by direct sequencing at baseline. Among participants who had mutations, we calcualted the rate of SVR12.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir Plus Elbasvir</title>
            <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With NS3/4A or NS5A Muttations Who Achieved SVR12</title>
          <description>We identified the NS3/4A or NS5A muttations by direct sequencing at baseline. Among participants who had mutations, we calcualted the rate of SVR12.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Grazoprevir Plus Elbasvir</title>
          <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
Grazoprevir plus Elbasvir: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Serious ALT elevation</sub_title>
                <description>ALT&gt;300 U/L during treatment</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eiichi Ogawa / Assistant Professor</name_or_title>
      <organization>Kyushu University Hospital</organization>
      <phone>81926425909</phone>
      <email>eogawa@gim.med.kyushu-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

